Рынок обнаружения и диагностики генов CRISPR в Азиатско-Тихоокеанском регионе – тенденции отрасли и прогноз до 2029 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок обнаружения и диагностики генов CRISPR в Азиатско-Тихоокеанском регионе – тенденции отрасли и прогноз до 2029 года

  • Medical Devices
  • Published Report
  • May 2022
  • Asia-Pacific
  • 350 Pages
  • Количество таблиц: 216
  • Количество рисунков: 48

>Рынок обнаружения и диагностики генов CRISPR в Азиатско-Тихоокеанском регионе по классам (класс 1 — множественные эффекторные белки и класс 2 — одиночный белок, связывающий CrRNA), продукты и услуги (продукты и услуги), применение (биомедицинская диагностика, генная инженерия , разработка лекарственных средств, сельскохозяйственные приложения и другие), рабочий процесс (подготовка образцов, предварительная амплификация, CrRNA, ферменты Cas и зондирование), конечный пользователь ( больницы , диагностические центры, биотехнологические компании, академические и научно-исследовательские институты и другие), канал распространения (прямой тендер, розничные продажи) Тенденции отрасли и прогноз до 2029 г.

Азиатско-Тихоокеанский рынок обнаружения и диагностики генов CRISPR

Определение рынка и его понимание

CRISPR — это кластеризованные, регулярно расположенные короткие палиндромные повторы, инструмент для редактирования генома, позволяющий исследователям легко изменять последовательности ДНК и модифицировать функцию генов. Он имеет множество потенциальных применений, включая исправление генетических дефектов, лечение и профилактику распространения заболеваний. Диагностика на основе CRISPR использовалась для многих биомедицинских приложений, таких как обнаружение биомаркеров инфекционных и неинфекционных заболеваний на основе нуклеиновых кислот и обнаружение генетических заболеваний. Наборы для анализа в CRISPR состоят из двух компонентов: белка Cas9 и направляющей РНК, цепочки молекул нуклеиновых кислот с определенным генетическим кодом.

Рынок обнаружения и диагностики генов CRISPR

Рынок обнаружения и диагностики генов CRISPR

Эта система CRISPR-Cas9 была модифицирована для использования в клетках млекопитающих. Мы можем либо выбить определенные гены, введя направляющую последовательность (sgRNA), специфичную для нашего интересующего гена, введя мутации сдвига рамки считывания посредством негомологичного соединения концов (NHEJ), либо сгенерировать мутации knock-in.

Системы CRISPR-Cas 9 расширили сферу диагностики и услуг в области генной и клеточной терапии. Фармацевтические компании вкладывают значительные средства в НИОКР для разработки новых продуктов, при этом всплеск генных и клеточных терапевтических агентов выходит на раннюю стадию разработки. Инвестиции участников рынка позволят производить безопасные и эффективные методы лечения для пациентов, которым это действительно необходимо.

Азиатско-Тихоокеанское обнаружение и диагностика гена CRISPR является поддерживающим и направлено на снижение тяжести симптомов. Data Bridge Market Research анализирует, что рынок обнаружения и диагностики гена CRISPR будет расти в среднем на 21,6% в течение прогнозируемого периода с 2022 по 2029 год.

Отчет Метрика

Подробности

Прогнозируемый период

2022-2029

Базовый год

2021

Исторические годы

2020 (Можно настроить на 2019 - 2014)

Количественные единицы

Доход в млн. долл. США, цены в долл. США

Охваченные сегменты

By Class (Class 1- Multiple Effector Proteins And Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services.), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications And Others.), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes And Sensing.), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic And Research Institutes And Others) Distribution Channel (Direct Tender, Retail Sales),

Countries Covered

China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines And Rest Of Asia-Pacific

Market Players Covered

GenScript, Takara Bio Inc., OriGene Technologies, Inc., Agilent Technologies, Inc., Synthego, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher) Thermo Fisher Scientific Inc. among others.

 Asia-Pacific CRISPR Gene Detection and Diagnostic Market Dynamics

Drivers

  • Rise in prevalence and incidence of chronic diseases

Chronic diseases are common health conditions, where one in three the adults suffer from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens.

CRISPR is abbreviated as clustered regularly interspaced short palindromic repeats. In recent years, CRISPR has become a commanding tool for gene editing, which is used to alter the specific sequences of DNA in a cell. CRISPR has important use in the research and treatment of Huntington’s disease, muscular dystrophy, cancer and high cholesterol.

For instance,

  • In 2021, the data by NORD - National Organization for Rare Disorders, Inc. stated the diagnosed incidence of Duchenne Muscular Dystrophy (DMD). The Duchenne Muscular Dystrophy (DMD) is a frequent genetic condition, which affects 1 in 3,500 male births worldwide
  • Rise In Investment In Research And Development

Gene editing technologies, such as the CRISPR-Cas 9 system, have extended the scope of diagnostics and services in gene and cell therapies. Pharmaceutical companies invest heavily in R&D to develop new products, with a surge of gene and cell therapy agents entering early development. The market players investing would allow to achieve the goal of producing safe and effective treatments for patients in serious need.

For instance,

  • In February 2022, Synthego had raised USD 200 million as an investment for research and development to boost the development of CRISPR-Based Medicines from early-phase research to the clinic. Synthego will use the investment amount from Series E finance to accelerate the creation of CRISPR diagnostics and services

Availability of funding for CRISPR gene diagnostics

CRISPR gene diagnostics and research are funded by the National Institute of Health (NIH) budget. The private sector also funds the CRISPR gene detection and research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With genome editing being such a new field, an unbiased governmental body must supervise them; the FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries., will further enhance the growth of the CRISPR gene detection and diagnostic market.

Furthermore, advancement in CRISPR gene diagnostics, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the Asia-Pacific CRISPR gene detection market. Other factors such as increase in the demand for effective therapies and rising awareness about the timely diagnosis and will positively impact the CRISPR gene detection and diagnostic market's growth rate. Additionally, high disposable income, rising number of chronic diseases, changing lifestyle will result in the expansion of the CRISPR gene detection and diagnostic market. 

Opportunities

  • The rise in healthcare expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

  • Strategic initiative by market players

The demand for CRISPR gene detection and diagnosis has increased the demand in the U.S. and Asia-Pacific owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

  • In May 2021, Horizon Discovery Ltd. extended the gene modulation portfolio with the first synthetic single guide RNA and patent pending dcas9 repressor for CRISPR interference in Waltham. The expansion of the portfolio had increased the sales and revenue of the synthetic guide RNA portfolio across the U.S. and the U.K. region and had increased the collaboration with market players

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the CRISPR gene detection and diagnostic market in the forecast period of 2022-2029. Also, high unmet need of current and developments in healthcare technology will escalate the growth rate of the CRISPR gene detection and diagnostic market in future.

Restraints/Challenges

However, high cost of CRISPR diagnostics and risks faced while using the CRISPR diagnostics will impede the growth rate of CRISPR gene detection and diagnostic market. Additionally, the risks incurred while using the MRI devices will hinder the CRISPR gene detection and diagnostic market growth. The lack of skilled expertise and regulations will further challenge the market in the forecast period mentioned above.

  • Rise in cost of CRISPR based diagnostics

The vast potential of CRISPR based therapeutics comes with a cost tag. Maximum genome editing therapies require an increased amount of time for development and production, and hence the rise in cost occurs. Besides, the assay kits and medications related to CRISPR gene detection and diagnostic are applicable to large section of population. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend in the future.

For instance,

  • In July 2021, according to Integrated DNA Technologies, Inc., the first commercially available CRISPR-based diagnostic assay for SARS-CoV-2 including reverse transcription LAMP (RT-LAMP) as preamplification is currently available at USD 30.15 per reaction

The CRISPR gene detection and diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on CRISPR gene detection and diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to a study by Globocan. In 2020, breast cancer had high incidence of cases, around 11.7%, followed by lung cancer which is 11.40%, colorectum cancer which is 10.00%, and cervix uteri and oesophagus cancer having less number of incident cases.

CRISPR gene detection and diagnostic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on the CRISPR Gene Detection and Diagnostic Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In August 2020, SHERLOCK BIOSCIENCES announced a collaboration with Dartmouth-Hitchcock Health, to conduct the clinical trial of SHERLOCK Diagnostic Kit for Sars-CoV-2. The kit received emergency approval from the Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

Asia-Pacific CRISPR Gene Detection and Diagnostic Market Scope

The  CRISPR gene detection and diagnostic market is segmented on the basis of six segments: class, products & services, application, workflow, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

  • Class 1- Multiple Effector Proteins
  • Class 2 -Single CrRNA Binding Protein

On the basis of class, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single CrRNA binding protein.

Products & Services

  • Products
  • Services

On the basis of products & services, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into products & services.

Application

  • Biomedical Diagnostics
  • Genome Engineering
  •  Drug Discovery
  • Agricultural Applications
  • Others

On the basis of application, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others.

Workflow

  • Sample Preparation
  • Pre-Amplification
  • CrRNA
  • Cas Enzymes
  • Sensing

On the basis of workflow, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, CrRNA, Cas enzymes and sensing.

End User

  • Hospitals
  • Diagnostic Centers
  • Biotechnology Companies
  • Academic and Research Institutes
  • Others

On the basis of end user, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others.

Distribution Channel

  • Direct Tenders
  • Retail Sales

Рынок обнаружения и диагностики генов CRISPR

On the basis of distribution channel, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into direct tenders and retail sales.

CRISPR Gene Detection and Diagnostic Market Regional Analysis/Insights

Проведен анализ рынка обнаружения и диагностики генов CRISPR в Азиатско-Тихоокеанском регионе, а также предоставлены сведения о размерах рынка и тенденциях по регионам, классам, продуктам и услугам, применению, рабочему процессу, конечным пользователям и каналам сбыта, как указано выше.

В отчете о рынке обнаружения и диагностики генов CRISPR рассматриваются следующие страны: Китай, Япония, Южная Корея, Индия, Австралия, Сингапур, Таиланд, Малайзия, Индонезия, Филиппины и остальные страны Азиатско-Тихоокеанского региона.

Китай доминирует на рынке обнаружения и диагностики гена CRISPR благодаря росту клинических испытаний диагностики на основе CRISPR.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка внутри страны, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демография страны, эпидемиология заболеваний и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность брендов Азиатско-Тихоокеанского региона и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние каналов продаж.

Конкурентная среда и анализ доли рынка обнаружения и диагностики генов CRISPR

Конкурентная среда рынка обнаружения и диагностики гена CRISPR в Азиатско-Тихоокеанском регионе содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, присутствие в Азиатско-Тихоокеанском регионе, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование приложений. Приведенные выше данные относятся только к фокусу компаний, связанному с рынком обнаружения и диагностики гена CRISPR.

Среди основных игроков, работающих на рынке обнаружения и диагностики генов CRISPR, можно назвать GenScript, Takara Bio Inc., OriGene Technologies, Inc., Agilent Technologies, Inc., Synthego, Merck KGaA, Integrated DNA Technologies, Inc. (дочерняя компания Danaher), Thermo Fisher Scientific Inc. и другие.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 CLASS SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE)

6 EPIDEMIOLOGY

7 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO

8 PIPELINE ANALYSIS FOR ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES

9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT

9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS

9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC

9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS

9.2 RESTRAINTS

9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS

9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS

9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH

9.2.4 AVAILABILITY OF ALTERNATIVES

9.3 OPPORTUNITIES

9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

9.3.2 RISE IN HEALTHCARE EXPENDITURE

9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS

9.4 CHALLENGES

9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS

9.4.2 STRINGENT REGULATIONS

10 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS

10.1 OVERVIEW

10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN

10.2.1 BIOMEDICAL DIAGNOSTICS

10.2.2 AGRICULTURAL APPLICATIONS

10.2.3 GENOME ENGINEERING

10.2.4 DRUG DISCOVERY

10.2.5 OTHERS

10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS

11 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES

11.1 OVERVIEW

11.2 PRODUCTS

11.2.1 ASSAY KITS

11.2.1.1 SGRNA KIT

11.2.1.2 GENOMIC DETECTION KIT

11.2.1.3 OTHERS

11.2.2 PROTEINS

11.2.2.1 CAS9

11.2.2.2 CPF1

11.2.2.3 OTHERS

11.2.3 PLASMID AND VECTOR

11.2.4 LIBRARY

11.2.5 CONTROL KITS

11.2.6 DELIVERY SYSTEM PRODUCTS

11.2.7 DESIGN TOOLS

11.2.8 GENOMIC RNA

11.2.9 HDR BLOCKERS

11.2.9.1 AZIDOTHYMIDINE

11.2.9.2 TRIFLUOROTHYMIDINE

11.2.9.3 OTHERS

11.2.9.4 OTHERS

11.3 SERVICES

11.3.1 G-RNA DESIGN

11.3.2 CELL LINE ENGINEERING

11.3.3 MICROBIAL GENE EDITING

11.3.4 DNA SYNTHESIS

11.3.5 OTHERS

12 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 BIOMEDICAL DIAGNOSTICS

12.2.1 CANCER

12.2.2 BLOOD DISORDERS

12.2.3 HEREDITARY DISORDERS

12.2.4 MUSCULAR DYSTROPHY

12.2.5 AIDS

12.2.6 NEURODEGENERATIVE CONDITION

12.2.7 OTHERS

12.3 AGRICULTURAL APPLICATIONS

12.4 GENOME ENGINEERING

12.4.1 CELL LINE ENGINEERING

12.4.2 HUMAN STEM CELLS

12.5 DRUG DISCOVERY

12.6 OTHERS

13 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW

13.1 OVERVIEW

13.2 CRRNA

13.3 CAS ENZYME

13.4 PRE-AMPLIFICATION

13.4.1 PCR

13.4.2 LAMP

13.4.3 RPA

13.5 SAMPLE PREPARATION

13.6 SENSING

13.6.1 FLUORESCENT PROBES

13.6.2 COLORIMETRIC

14 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER

14.1 OVERVIEW

14.2 BIOTECHNOLOGY COMPANIES

14.3 ACADEMIC AND RESEARCH INSTITUTES

14.4 DIAGNOSTIC CENTERS

14.5 HOSPITALS

14.6 OTHERS

15 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

16 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 INDIA

16.1.4 SOUTH KOREA

16.1.5 AUSTRALIA

16.1.6 SINGAPORE

16.1.7 THAILAND

16.1.8 PHILIPPINES

16.1.9 MALAYSIA

16.1.10 INDONESIA

16.1.11 REST OF ASIA-PACIFIC

17 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 THERMO FISHER SCIENTIFIC INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 MERCK KGA

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 AGILENT TECHNILOGIES, INC

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER)

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 GENSCRIPT

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 10 X GENOMICS

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.7 APPLIED STEM CELL

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 ADDGENE

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOVISION INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CELLECTA, INC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 CAS TAG BIOSCIENCES

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 GENECOPOEIA, INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 HORIZON DISCOVERY LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 HERA BIOLABS

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 NEW ENGLAND BIOLABS

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 ORIGENE TECHNOLOGIES, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SYNTHEGO

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TAKARA BIO INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 TOOLGEN, INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Список таблиц

TABLE 1 PIPELINE ANALYSIS FOR ASIA PACIFIC CRISPR GENE THERAPEUTICS

TABLE 2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC CLASS-1 MULTIPLE EFFECTOR PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC AGRICULTURAL APPLICATIONS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC DRUG DISCOVERYIN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC CRRNA IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC CAS ENZYME IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC SAMPLE PREPARATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC BIOTECHNOLOGY COMPANIES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC DIAGNOSTIC CENTERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC HOSPITALS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC DIRECT TENDER IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC RETAIL SALES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 53 ASIA-PACIFIC SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 54 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 57 CHINA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 59 CHINA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CHINA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 61 CHINA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 62 CHINA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 63 CHINA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 CHINA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 66 CHINA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 67 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 68 CHINA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 69 CHINA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 70 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 71 CHINA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 73 JAPAN CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 75 JAPAN PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 JAPAN ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 77 JAPAN HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 78 JAPAN PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 79 JAPAN SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 JAPAN GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 JAPAN BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 84 JAPAN PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 85 JAPAN SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 86 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 87 JAPAN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 88 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 89 INDIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 90 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 91 INDIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 INDIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 93 INDIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 94 INDIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 95 INDIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 97 INDIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 98 INDIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 99 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 100 INDIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 101 INDIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 102 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 103 INDIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 104 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 105 SOUTH KOREA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 106 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 107 SOUTH KOREA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 SOUTH KOREA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 109 SOUTH KOREA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 110 SOUTH KOREA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 111 SOUTH KOREA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 113 SOUTH KOREA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 114 SOUTH KOREA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 115 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 116 SOUTH KOREA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 117 SOUTH KOREA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 118 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 119 SOUTH KOREA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 120 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 121 AUSTRALIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 122 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 123 AUSTRALIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 AUSTRALIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 125 AUSTRALIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 126 AUSTRALIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 127 AUSTRALIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 129 AUSTRALIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 130 AUSTRALIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 131 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 132 AUSTRALIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 133 AUSTRALIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 134 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 135 AUSTRALIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 136 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 137 SINGAPORE CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 138 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 139 SINGAPORE PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 SINGAPORE ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 141 SINGAPORE HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 142 SINGAPORE PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 143 SINGAPORE SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 145 SINGAPORE GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 146 SINGAPORE BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 147 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 148 SINGAPORE PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 149 SINGAPORE SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 150 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 151 SINGAPORE CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 152 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 153 THAILAND CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 154 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 155 THAILAND PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 THAILAND ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 157 THAILAND HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 158 THAILAND PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 159 THAILAND SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 161 THAILAND GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 162 THAILAND BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 163 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 164 THAILAND PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 165 THAILAND SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 166 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 167 THAILAND CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 168 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 169 PHILIPPINES CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 170 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 171 PHILIPPINES PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 PHILIPPINES ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 173 PHILIPPINES HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 174 PHILIPPINES PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 175 PHILIPPINES SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 177 PHILIPPINES GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 178 PHILIPPINES BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 179 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 180 PHILIPPINES PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 181 PHILIPPINES SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 182 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 183 PHILIPPINES CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 184 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 185 MALAYSIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 186 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 187 MALAYSIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 MALAYSIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 189 MALAYSIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 190 MALAYSIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 191 MALAYSIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 193 MALAYSIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 194 MALAYSIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 195 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 196 MALAYSIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 197 MALAYSIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 198 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 199 MALAYSIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 200 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 201 INDONESIA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 202 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 203 INDONESIA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 204 INDONESIA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 205 INDONESIA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 206 INDONESIA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 207 INDONESIA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 208 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 209 INDONESIA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 210 INDONESIA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 211 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 212 INDONESIA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 213 INDONESIA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 214 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 215 INDONESIA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 216 REST OF ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

Список рисунков

FIGURE 1 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN TECHNOLOGICAL ADVANCEMENTS IN CRISPR DIAGNOSTICS, AND GOVERNMENT FUNDING FOR THE DEVELOPMENT OF CRISPR DETECTION KITS ARE EXPECTED TO DRIVE THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 TO 2029

FIGURE 13 CLASS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 & 2029

FIGURE 14 ASIA PACIFIC CRISPR GENE PATENT SCENARIO, BY APPLICATION

FIGURE 15 CRISPR PATENT LANDSCAPE AND NUMBER OF APPLICATIONS OF NEW PATENT FAMILIES FILED WORLDWIDE, 2001 TO 2019

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET

FIGURE 17 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020

FIGURE 18 PREVALENCE OF HUNTINGTON’S DISEASE IN 2019

FIGURE 19 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2021

FIGURE 20 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2022-2029 (USD MILLION)

FIGURE 21 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, CAGR (2022-2029)

FIGURE 22 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, LIFELINE CURVE

FIGURE 23 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2021

FIGURE 24 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2022-2029 (USD MILLION)

FIGURE 25 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2022-2029)

FIGURE 26 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE

FIGURE 27 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2021

FIGURE 28 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 29 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 30 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2021

FIGURE 32 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2022-2029 (USD MILLION)

FIGURE 33 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, CAGR (2022-2029)

FIGURE 34 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, LIFELINE CURVE

FIGURE 35 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 36 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 37 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 41 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 44 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 45 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47 ASIA-PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS (2022 & 2029)

FIGURE 48 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

On the basis of application, the Asia-Pacific CRISPR Gene Detection and Diagnostic Market is segmented into Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others.
The Asia-Pacific CRISPR Gene Detection and Diagnostic Market is to grow at a CAGR of 21.6% during the forecast by 2029.
The major players operating in the Asia-Pacific CRISPR Gene Detection and Diagnostic Market are GenScript, Takara Bio Inc., OriGene Technologies, Inc., Agilent Technologies, Inc., Synthego, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher) Thermo Fisher Scientific Inc. among others..
The major countries covered in the Asia-Pacific CRISPR Gene Detection and Diagnostic Market are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines And Rest Of Asia-Pacific.